1. Field of the Invention
The present invention relates to the healing of wounds. More particularly, the invention relates to a vacuum assisted wound closure system wherein a foam pad is modified to facilitate wound healing by including phototherapy compatible optical fibers.
2. Background of the Invention
Wound closure involves the inward migration of epithelial and subcutaneous tissue adjacent the wound. This migration is ordinarily assisted through the inflammatory process, whereby blood flow is increased and various functional cell types are activated. Through the inflammatory process, blood flow through damaged or broken vessels is stopped by capillary level occlusion, whereafter cleanup and rebuilding operations may begin. Unfortunately, this process is hampered when a wound is large or has become infected. In such wounds, a zone of stasis (i.e. an area in which localized swelling of tissue restricts the flow of blood to the tissues) forms near the surface of the wound.
Without sufficient blood flow, the epithelial and subcutaneous tissues surrounding the wound not only receive diminished oxygen and nutrients, but are also less able to successfully fight bacterial infection and thus are less able to naturally close the wound. Until recently, such difficult wounds were addressed only through the use of sutures or staples. Although still widely practiced and often effective, such mechanical closure techniques suffer a major disadvantage in that they produce tension on the skin tissue adjacent the wound. In particular, the tensile force required in order to achieve closure using sutures or staples causes very high localized stresses at the suture or staple insertion point. These stresses commonly result in the rupture of the tissue at the insertion points, which can eventually cause wound dehiscence and additional tissue loss.
Additionally, some wounds harden and inflame to such a degree due to infection that closure by stapling or suturing is not feasible. Wounds not reparable by suturing or stapling generally require prolonged hospitalization, with its attendant high cost, and major surgical procedures, such as grafts of surrounding tissues. Examples of wounds not readily treatable with staples or suturing include large, deep, open wounds; decubitus ulcers; ulcers resulting from chronic osteomyelitis; and partial thickness burns that subsequently develop into full thickness burns.
As a result of these and other shortcomings of mechanical closure devices, methods and apparatus for draining wounds by applying continuous negative pressures have been developed. When applied over a sufficient area of the wound, such negative pressures have been found to promote the migration toward the wound of epithelial and subcutaneous tissues. In practice, the application to a wound of negative gauge pressure, commercialized by Applicant under the designation “Vacuum Assisted Closure” (or “V.A.C.”) therapy, typically involves the mechanical-like contraction of the wound with simultaneous removal of excess fluid. In this manner, VAC therapy augments the body's natural inflammatory process while alleviating many of the known intrinsic side effects, such as the production of edema caused by increased blood flow absent the necessary vascular structure for proper venous return.
While V.A.C.® therapy has been highly successful in the promotion of wound closure, healing many wounds previously thought largely untreatable, some difficulty remains. Because the very nature of V.A.C. therapy dictates an atmospherically sealed wound site, the therapy must often be performed to the exclusion of other beneficial, and therefore desirable, wound treatment modalities. One such excluded modality is phototherapy—a method for wound treatment wherein appropriate wavelengths of light are directed into or about the wound bed.
Phototherapy has to date been regarded as impossible or at least impracticable in combination with V.A.C. therapy due to the utilization of opaque materials in the administration of V.A.C. therapy. In particular, the use of an opaque foam pad for within the wound site, as is known to those of ordinary skill in the V.A.C.-related arts, requires that the V.A.C. therapy be disrupted and the dressings removed in order that phototherapy can be performed. Because phototherapy and the like are nonetheless desirable in combination with V.A.C. therapy, it is a primary object of the present invention to provide a V.A.C. therapy wound dressing that is compatible with such therapies.
It is a further object of the present invention to provide such a dressing that is also readily adaptable to a variety of wound sizes and shapes and that requires no inordinate modification of known procedures for or administration of V.A.C. therapy.
It is yet a further object of the present invention to provide such a dressing that is economical and disposable, but also safe for general patient use.
In accordance with the foregoing objects, the present invention—a modified vacuum assisted wound closure system adapted for concurrent applications of phototherapy—generally comprises a foam pad for insertion substantially into the wound site and a wound drape for sealing enclosure of the foam pad at the wound site. According to the invention, the foam pad is modified to comprise an optical pigtail, whereby a desired wavelength of light may be directed into and about the wound site. Although the foam pad is placed in fluid communication with a vacuum source for promotion of fluid drainage, as known in the art, the addition of the optical pigtail is noninvasive to the known V.A.C. therapy and requires no modification thereof.
According to the preferred embodiment of the present invention, the foam pad preferably comprises a highly reticulated, open-cell polyurethane or polyether foam for good permeability of wound fluids while under suction, as previously known in the art. However, the foam pad of the present invention is also provided with an optical pigtail. This optical pigtail comprises an optical fiber that has been formed to fan into a plurality of sections, much like a capillary vessel system. The fibers of the most distal fanned sections, which are implanted in the foam pad at its base, are provided with tiny optical slots, preferably oriented away from the foam pad and toward the wound site.
Each optical slot is made by stripping the cladding from the optical fiber in the desired areas of the fanned sections. In this manner, the slots form slot radiators, each of which is thereby adapted to illuminate a portion of the wound site. Because it is often necessary to trim the foam pad in ordinary preparation for V.A.C. therapy wound treatment, the optical fibers preferably comprise plastic cores and claddings, which is appropriate for those wavelengths in the visible and near infrared as are typically utilized in phototherapy applications. One such material as may be employed is acrylic, which is inexpensive and easy to cut, but those of ordinary skill in the art will recognize many substantial equivalents, such as styrene, which although more expensive and brittle, may also suffice if an ultraviolet application is required. Other materials and adaptations may be utilized in alternative embodiments. The particulars of such alternatives will depend on the particularities of the applications and on the wavelength, intensity and other properties of the electromagnetic energy being delivered in conjunction with the V.A.C. therapy.
Upon placement of the pad, having the optical pigtail embedded therein, the wound drape is firmly adhered about the V.A.C. therapy suction hose as well as the extending optical fiber to prevent vacuum leakage. In use the V.A.C. therapy is conducted as known and, if desired, phototherapy is added by simply illuminating the optical slot radiators through the fiber. In this manner, phototherapy may be conveniently combined with existing V.A.C. therapies, without loss of V.A.C. therapy performance and without inconvenience or overly increased cost.
Finally, many other features, objects and advantages of the present invention will be apparent to those of ordinary skill in the relevant arts, especially in light of the foregoing discussions and the following drawings and exemplary detailed description.
Although the scope of the present invention is much broader than any particular embodiment, a detailed description of the preferred embodiment follows together with illustrative figures, wherein like reference numerals refer to like components, and wherein:
Although those of ordinary skill in the art will readily recognize many alternative embodiments, especially in light of the illustrations provided herein, this detailed description is exemplary of the preferred embodiment of the present invention, the scope of which is limited only by the claims which may be drawn hereto.
Referring now to the figures, the present invention 10 is shown to generally comprise a foam pad 11 for insertion substantially into the wound site 12 and a wound drape 13 for sealing enclosure of the foam pad 11 at the wound site 12. According to the invention, the foam pad 11 is modified to comprise an optical pigtail 14, whereby a desired wavelength of light, within a significant portion of the spectrum between approximately 300 nm and approximately 1500 nm, may be directed into and about the wound site 12. After insertion into the wound site 12 and sealing with the wound drape 13, the foam pad 11 is placed in fluid communication with a vacuum source for promotion of fluid drainage, as known to those of ordinary skill in the art. Although the foam pad 11 is modified from prior art pads in that the pad 11 of the present invention comprises the optical pigtail 14, the optical pigtail 14 is noninvasive to the known V.A.C. therapy and requires no modification thereof.
According to the preferred embodiment of the present invention, the foam pad 11, wound drape 13 and vacuum source are implemented as known in the prior art, with the exception of those modifications to the foam pad 11 detailed further herein. Each of these components is detailed in U.S. patent application Ser. No. 08/517,901 filed Aug. 22, 1995. By this reference, the full specification of U.S. patent application Ser. No. 08/517,901 (“the '901 application”), including the claims and the drawings, is incorporated herein as though now set forth in its entirety.
As detailed in the '901 application, the foam pad 11 preferably comprises a highly reticulated, open-cell polyurethane or polyether foam for good permeability of wound fluids while under suction. As also detailed in the '901 application, the foam pad 11 is preferably placed in fluid communication, via a plastic or like material hose 15, with a vacuum source, which preferably comprises a canister safely placed under vacuum through fluid communication, via an interposed hydrophobic membrane filter, with a vacuum pump. Finally, the '901 application also details the wound drape 13, which preferably comprises an elastomeric material at least peripherally covered with a pressure sensitive, acrylic adhesive for sealing application over the wound site 12.
According to the preferred method of the present invention, those components as are described in the '901 application are generally employed as known in the art with the exception that the foam pad 11 is provided with an optical pigtail 14. Referring to
Each optical slot 19 is made by stripping the cladding from the optical fiber 16 in the desired areas of the fanned sections 17. In this manner, the slots 19 form slot radiators 20, each of which is thereby adapted to illuminate a portion of the wound site 12. Because it is necessary to trim the foam pad 11 in preparation for V.A.C. therapy wound treatment, the optical fibers 16 preferably comprise plastic cores and claddings, which is appropriate for those wavelengths in the visible and near infrared as are typically utilized in phototherapy applications. One such material as may be employed is acrylic, which is inexpensive and easy to cut, but those of ordinary skill in the art will recognize many substantial equivalents, such as styrene, which although more expensive and brittle, may also suffice if an ultraviolet application is required.
Upon placement of the pad 11, having the optical pigtail 14 embedded therein, the wound drape 13 is firmly adhered about the V.A.C. therapy hose 15 as well as the extending optical fiber 16 to prevent vacuum leakage. In use the V.A.C. therapy is conducted as known and, if desired, phototherapy is added by simply illuminating the optical slot radiators 20 through the fiber 16. In this manner, phototherapy may be conveniently combined with existing V.A.C. therapies, without loss of V.A.C. therapy performance and without inconvenience or overly increased cost.
While the foregoing description is exemplary of the preferred embodiment of the present invention, those of ordinary skill in the relevant arts will recognize the many variations, alterations, modifications, substitutions and the like as are readily possible, especially in light of this description and the accompanying drawings. For example, the known foam pad 11 as presently implemented may be entirely replaced with a plasticized, acrylimide foam, whereby light may be directly transferred therethrough and into the wound site 12. Other embodiments may utilize an electrical current through a coiled conductor (or other form of electromagnetic energy emitter) coupled with or embedded in pad 11 in order to generate any desired form of electromagnetic energy. In any case, because the scope of the present invention is much broader than any particular embodiment, the foregoing detailed description should not be construed as a limitation of the scope of the present invention, which is limited only by the claims that may be drawn hereto.
The present invention claims the benefit, under 35 U.S.C. § 119(e), of the filing of U.S. provision patent application Ser. No. 60/127,936 filed Apr. 6, 1999.
Number | Name | Date | Kind |
---|---|---|---|
1355846 | Rannells | Oct 1920 | A |
2547758 | Keeling | Apr 1951 | A |
2632443 | Lesher | Mar 1953 | A |
2682873 | Evans et al. | Jul 1954 | A |
2969057 | Simmons | Jan 1961 | A |
3367332 | Groves | Feb 1968 | A |
3520300 | Flower | Jul 1970 | A |
3648692 | Wheeler | Mar 1972 | A |
3682180 | McFarlane | Aug 1972 | A |
3826254 | Mellor | Jul 1974 | A |
4080970 | Miller | Mar 1978 | A |
4096853 | Weigand | Jun 1978 | A |
4139004 | Gonzalez | Feb 1979 | A |
4165748 | Johnson | Aug 1979 | A |
4233969 | Lock et al. | Nov 1980 | A |
4245630 | Lloyd et al. | Jan 1981 | A |
4261363 | Russo | Apr 1981 | A |
4275721 | Olson | Jun 1981 | A |
4284079 | Adair | Aug 1981 | A |
4297995 | Golub | Nov 1981 | A |
4333468 | Geist | Jun 1982 | A |
4373519 | Errede et al. | Feb 1983 | A |
4382441 | Svedman | May 1983 | A |
4392853 | Muto | Jul 1983 | A |
4392858 | George et al. | Jul 1983 | A |
4419097 | Rowland | Dec 1983 | A |
4475909 | Eisenberg | Oct 1984 | A |
4480638 | Schmid | Nov 1984 | A |
4525166 | Leclerc | Jun 1985 | A |
4525374 | Vaillancourt | Jun 1985 | A |
4540412 | Van Overloop | Sep 1985 | A |
4543100 | Brodsky | Sep 1985 | A |
4551139 | Plaas et al. | Nov 1985 | A |
4569348 | Hasslinger | Feb 1986 | A |
4605399 | Weston et al. | Aug 1986 | A |
4608041 | Nielsen | Aug 1986 | A |
4640688 | Hauser | Feb 1987 | A |
4655754 | Richmond et al. | Apr 1987 | A |
4710165 | McNeil et al. | Dec 1987 | A |
4733659 | Edenbaum et al. | Mar 1988 | A |
4743232 | Kruger | May 1988 | A |
4758220 | Sundblom et al. | Jul 1988 | A |
4787888 | Fox | Nov 1988 | A |
4826949 | Stanko | May 1989 | A |
4838883 | Matsuura | Jun 1989 | A |
4840187 | Brazier | Jun 1989 | A |
4863449 | Therriault et al. | Sep 1989 | A |
4872450 | Austad | Oct 1989 | A |
4878901 | Sachse | Nov 1989 | A |
4897081 | Poirier et al. | Jan 1990 | A |
4906233 | Moriuchi et al. | Mar 1990 | A |
4906240 | Reed et al. | Mar 1990 | A |
4919654 | Kalt | Apr 1990 | A |
4941882 | Ward et al. | Jul 1990 | A |
4953565 | Tachibana et al. | Sep 1990 | A |
4969702 | Anderson | Nov 1990 | A |
4969880 | Zamierowski | Nov 1990 | A |
4985019 | Michelson | Jan 1991 | A |
5037397 | Kalt et al. | Aug 1991 | A |
5086170 | Luheshi et al. | Feb 1992 | A |
5092858 | Benson et al. | Mar 1992 | A |
5100396 | Zamierowski | Mar 1992 | A |
5100429 | Sinofsky et al. | Mar 1992 | A |
5134994 | Say | Aug 1992 | A |
5149331 | Ferdman et al. | Sep 1992 | A |
5167613 | Karami et al. | Dec 1992 | A |
5176663 | Svedman et al. | Jan 1993 | A |
5232453 | Plass et al. | Aug 1993 | A |
5261893 | Zamierowski | Nov 1993 | A |
5278100 | Doan et al. | Jan 1994 | A |
5279550 | Habib et al. | Jan 1994 | A |
5298015 | Komatsuzaki et al. | Mar 1994 | A |
5344415 | DeBusk et al. | Sep 1994 | A |
5358494 | Svedman | Oct 1994 | A |
5358503 | Bertwell et al. | Oct 1994 | A |
5437622 | Carion | Aug 1995 | A |
5437651 | Todd et al. | Aug 1995 | A |
5474528 | Meserol | Dec 1995 | A |
5527293 | Zamierowski | Jun 1996 | A |
5549584 | Gross | Aug 1996 | A |
5556375 | Ewall | Sep 1996 | A |
5584296 | Cui et al. | Dec 1996 | A |
5607388 | Ewall | Mar 1997 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5645081 | Argenta et al. | Jul 1997 | A |
5766233 | Thiberg | Jun 1998 | A |
5976175 | Hirano et al. | Nov 1999 | A |
6071267 | Zamierowski | Jun 2000 | A |
6128797 | Shaffer | Oct 2000 | A |
6135116 | Vogel et al. | Oct 2000 | A |
6142982 | Hunt et al. | Nov 2000 | A |
6159236 | Biel | Dec 2000 | A |
6168591 | Sinofsky | Jan 2001 | B1 |
6187029 | Shapiro et al. | Feb 2001 | B1 |
6345623 | Heaton et al. | Feb 2002 | B1 |
6350168 | Kroll et al. | Feb 2002 | B1 |
6488643 | Tumey et al. | Dec 2002 | B1 |
6493568 | Bell et al. | Dec 2002 | B1 |
6553998 | Heaton et al. | Apr 2003 | B2 |
6814079 | Heaton et al. | Nov 2004 | B2 |
20020111537 | Taylor et al. | Aug 2002 | A1 |
20020115951 | Norstrem et al. | Aug 2002 | A1 |
20020120185 | Johnson | Aug 2002 | A1 |
20020143286 | Tumey | Oct 2002 | A1 |
20030187486 | Savage et al. | Oct 2003 | A1 |
20050010270 | Laufer | Jan 2005 | A1 |
Number | Date | Country |
---|---|---|
550575 | Aug 1982 | AU |
745271 | Mar 2002 | AU |
755496 | Dec 2002 | AU |
2005436 | Jun 1990 | CA |
26 40 413 | Mar 1978 | DE |
43 06 478 | Sep 1994 | DE |
295 04 378 | Sep 1995 | DE |
0117632 | Jan 1984 | EP |
0100148 | Feb 1984 | EP |
0161865 | Nov 1985 | EP |
0358 302 | Mar 1990 | EP |
1 018 967 | Aug 2004 | EP |
692578 | Jun 1953 | GB |
2 197 789 | Jun 1988 | GB |
2333965 | Aug 1999 | GB |
2329127 | Aug 2000 | GB |
71559 | Apr 2002 | SG |
WO 8002182 | Oct 1980 | WO |
WO 9309727 | May 1993 | WO |
WO9420041 | Sep 1994 | WO |
WO 9605873 | Feb 1996 | WO |
WO 9718007 | May 1997 | WO |
WO 9713793 | Sep 1997 | WO |
WO 9913793 | Sep 1998 | WO |
Number | Date | Country | |
---|---|---|---|
60127936 | Apr 1999 | US |